CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED

China Resources Pharmaceutical Group Limited

3320

HK0000311099

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:04 19/06/2024 pm IST			5-day change	1st Jan Change
6.02 ^HKD	+2.91%		+4.88%	+17.35%

11/06	China Resources Pharmaceutical to Cut Stake in Subsidiary	MT
07/06	China Resources Pharmaceutical Group Limited Announces Directorate Changes	CI

China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

May 30, 2024 at 05:46 pm IST

China Resources Pharmaceutical Group Limited announced that at the AGM held on 30 May 2024 approved a final dividend of RMB 0.154 per share for the year ended 31 December 2023.

Latest news about China Resources Pharmaceutical Group Limited

China Resources Pharmaceutical to Cut Stake in Subsidiary	11/06	MT
China Resources Pharmaceutical Group Limited Announces Directorate Changes	07/06	CI
China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	30/05	CI
China Resources Sanjiu, China Resources Power to Continue Cooperating on New Energy Projects	16/05	MT
China Resources Pharmaceutical Group Limited Announces Change of Company Secretary	24/04	CI
China Resources Pharma Unit Issues 3 Billion Yuan Bonds	18/04	MT
China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024	12/04	CI
China Resources Pharmaceutical Posts Gains in Full Year 2023 Profit	26/03	MT
China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024	26/03	CI
China Resources Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue	14/03	MT
Nomura Adjusts CR Pharmaceutical Group’s Price Target to HK$8.80 From HK$9.08, Keeps at Buy	11/03	MT
CR Sanjiu Expects Increase in 2023 Profit	25/01	MT
China Resources Pharmaceutical Unit Completes Capital Increase; Shares Fall 3%	08/01	MT
China Resources Pharmaceutical Unit Enters Share Subscription Deals to Boost Capital	29/12	MT
China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023	27/12	CI
China Resources Pharma Unit Boosts Stake in Jiangzhong Pharma Parent	27/12	MT
China Resources Pharmaceutical Subsidiary Begins Bidding for Potential Share Issuance	28/11	MT
China Resources Pharmaceutical Group Subsidiary Records Rise in Nine-Month Attributable Profit	01/11	MT
Dong-E-E-Jiao's Nine-Moth Profit Rises on Higher Revenue	31/23/31	MT
CR Boya Bio-Pharmaceutical's January-September Profit Increases	26/23/26	MT
Dong-E-E-Jiao Expects January-September Attributable Profit to Rise Up to 60%	11/23/11	MT
China Resources Pharma's Profit Marginally Rises in H1	31/23/31	MT
China Resources Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
CR Sanjiu Medical & Pharmaceutical's H1 Attributable Profit Rises 31%	30/23/30	MT

Chart China Resources Pharmaceutical Group Limited

Duration

Period

Chart China Resources Pharmaceutical Group Limited

More charts

CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Resources Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.02 HKD

Average target price

7.382 HKD

Spread / Average Target

+22.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED	+17.35%	4.71B
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+40.98%	629B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.42%	244B
ROCHE HOLDING AG	+2.17%	226B
NOVARTIS AG	+10.66%	215B
AMGEN INC.	+6.24%	164B

Other Pharmaceuticals